News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
23 January 2026

Exile Group partners with Bridgepoint to support next level...

Exile Group welcomes Bridgepoint, a leading mid-market investor, which will take a minority interest in the leading provider of events and intelligence for the export, trade,...

Perspective
26 January 2026

Venezuela: Not yet bankable or investable

The Trump administration’s capture of Nicolás Maduro was in part designed to create opportunities for US players in Venezuela’s oil sector. But both the short-term and...